



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

June 13, 2024

Christopher Gibson  
Chief Executive Officer and Director  
Recursion Pharmaceuticals, Inc.  
41 S Rio Grande Street  
Salt Lake City, UT 84101

**Re: Recursion Pharmaceuticals, Inc.**  
**Form 10-K for the Fiscal Year Ended December 31, 2023**  
**Filed February 29, 2024**  
**File No. 001-40323**

Dear Christopher Gibson:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences